Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire

Bulletin of the World Health Organization

Volumn 85, Issue 2, 2007, Pages 116-123

  Minga, Albert ^a   Danel, Christine ^a   Abo, Yao ^a   Dohoun, Lambert ^a   Bonard, Dominique ^a   Coulibaly, Ali ^a   Duvignac, Julien ^b   Dabis, François ^b   Salamonb, Roger ^b   Anglaret, Xavier ^b  

^a Programme PAC CI   (Côte d’Ivoire)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

ANTIBIOTICS; COHORT ANALYSIS; DISEASE CONTROL; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; MORBIDITY; WORLD HEALTH ORGANIZATION;

ADULT; ARTICLE; BACTERIAL INFECTION; BLOOD BANK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALARIA; MALE; MORBIDITY; PROPHYLAXIS; PROSPECTIVE STUDY; SEROCONVERSION; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COTE D'IVOIRE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; TIME FACTORS; WORLD HEALTH ORGANIZATION;

ABIDJAN; AFRICA; COTE D'IVOIRE; SUB-SAHARAN AFRICA; WEST AFRICA;

BACTERIA (MICROORGANISMS); HERPES ZOSTER; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33846782934     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.032292     Document Type: Article

References (20)

1. UNAIDS. WHO. AIDS epidemic update 2005. http://www.unaids.org/Epi2005/ doc/report.html
2. Salamon R, Marimoutou C, Ekra D, Minga A, Nerrienet E, Huet C, et al. Clinical and biological evolution of HIV-1 seroconverters in Abidjan, Cote d'Ivoire, 1997-2000. J Acquir Immune Defic Syndr 2002;29:149-57.
3. Anglaret X, Dakoury-Dogbo N, Bonard D, Toure S, Combe P, Ouassa T, et al. Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Cote d'Ivoire. AIDS 2002;16:909-18.
4. Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire. AIDS 2003;17:575-84.
5. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003;17:S5-15.
6. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Vol. 2004: http://www.who.int/3by5/publications/en/arv_eng.pdf
7. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: recommendations for a public health approach (2006 revision). Available from: http://www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20Guidelines.pdf.
8. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000;355:1131-7.
9. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006;42:709-15.
10. Deschamps MM, Fitzgerald DW, Pape JW, Johnson WD. HIV infection in Haiti: natural history and disease progression. AIDS 2000;14:2515-21.
11. Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown AE, et al. The Natural History of HIV-1 Infection in Young Thai Men After Seroconversion. J Acquir Immune Defic Syndr 2004;36:622-9.
12. Morgan D, Mahe C, Mayanja B, Whitworth J. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ 2002;324:193-6.
13. Begaud E, Feindirongai G, Versmisse P, Ipero J, Leal J, Germani Y, et al. Broad spectrum of coreceptor usage and rapid disease progression in HIV-1-infected individuals from Central African Republic. AIDS Res Hum Retroviruses 2003;19:551-60.
14. Anzala OA, Nagelkerke NJ, Bwayo JJ, Holton D, Moses S, Ngugi EN, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995;171:686-9.
15. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993;7:1569-79.
16. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Eotu H, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000;356:1051-6.
17. WHO. WHO Expert Consultation on Cotrimoxazole Prophylaxis in HIV Infection. WHO technical report series. Reference number: WHO/HIV/2006.01. Available from: http://www.who.int/hiv/pub/meetingreports/ctx/en/
18. Mermin J, Lule JR, Ekwaru JP, Pitter C. Should cotrimoxazole prophylaxis be taken by all adults with HIV in Africa? AIDS 2005;19:845-6.
19. Laird NM. Missing data in longitudinal studies. Stat Med 1988;7:305-15.
20. Morgan D, Mahe C, Mayanja B, Okongo J, Lubega R, Whitworth J. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002;16:597-603.